$16.3
0.92%
Downside
Day's Volatility :6.32%
Upside
5.45%
1.84%
Downside
52 Weeks Volatility :45.05%
Upside
44.02%
Period | Anika Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -33.71% | 0.0% | 0.0% |
6 Months | -38.73% | 4.2% | 0.0% |
1 Year | -19.48% | 15.2% | 0.0% |
3 Years | -62.09% | 10.5% | -27.4% |
Market Capitalization | 252.6M |
Book Value | $12.18 |
Earnings Per Share (EPS) | -6.86 |
PEG Ratio | 1.25 |
Wall Street Target Price | 26.5 |
Profit Margin | -59.4% |
Operating Margin TTM | -64.29% |
Return On Assets TTM | -4.01% |
Return On Equity TTM | -43.31% |
Revenue TTM | 164.2M |
Revenue Per Share TTM | 11.14 |
Quarterly Revenue Growth YOY | -6.5% |
Gross Profit TTM | 96.8M |
EBITDA | -8.2M |
Diluted Eps TTM | -6.86 |
Quarterly Earnings Growth YOY | -0.5 |
EPS Estimate Current Year | -1.45 |
EPS Estimate Next Year | 0.09 |
EPS Estimate Current Quarter | -0.01 |
EPS Estimate Next Quarter | 0.11 |
What analysts predicted
Upside of 62.58%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 105.6M | ↓ 6.93% |
Net Income | 18.7M | ↓ 41.16% |
Net Profit Margin | 17.74% | ↓ 10.31% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 114.6M | ↑ 8.58% |
Net Income | 27.2M | ↑ 45.25% |
Net Profit Margin | 23.73% | ↑ 5.99% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 130.5M | ↑ 13.83% |
Net Income | -24.0M | ↓ 188.19% |
Net Profit Margin | -18.38% | ↓ 42.11% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 147.8M | ↑ 13.29% |
Net Income | 4.1M | ↓ 117.24% |
Net Profit Margin | 2.8% | ↑ 21.18% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 156.2M | ↑ 5.71% |
Net Income | -14.9M | ↓ 459.43% |
Net Profit Margin | -9.51% | ↓ 12.31% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 166.7M | ↑ 6.67% |
Net Income | -82.7M | ↑ 456.34% |
Net Profit Margin | -49.6% | ↓ 40.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 44.3M | ↑ 16.82% |
Net Income | -2.7M | ↓ 73.52% |
Net Profit Margin | -6.19% | ↑ 21.1% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 41.5M | ↓ 6.4% |
Net Income | -6.6M | ↑ 139.91% |
Net Profit Margin | -15.86% | ↓ 9.67% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 43.0M | ↑ 3.63% |
Net Income | -63.0M | ↑ 858.03% |
Net Profit Margin | -146.61% | ↓ 130.75% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 40.5M | ↓ 5.7% |
Net Income | -4.5M | ↓ 92.83% |
Net Profit Margin | -11.14% | ↑ 135.47% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 41.9M | ↑ 3.45% |
Net Income | -88.0K | ↓ 98.05% |
Net Profit Margin | -0.21% | ↑ 10.93% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 38.8M | ↓ 7.56% |
Net Income | -29.9M | ↑ 33897.73% |
Net Profit Margin | -77.2% | ↓ 76.99% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 279.0M | ↓ 1.28% |
Total Liabilities | 15.4M | ↓ 19.58% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 330.7M | ↑ 18.54% |
Total Liabilities | 42.3M | ↑ 175.22% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 365.6M | ↑ 10.55% |
Total Liabilities | 93.2M | ↑ 120.18% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 347.5M | ↓ 4.94% |
Total Liabilities | 60.5M | ↓ 35.14% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 349.1M | ↑ 0.46% |
Total Liabilities | 63.6M | ↑ 5.15% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 270.6M | ↓ 22.48% |
Total Liabilities | 58.4M | ↓ 8.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 328.9M | ↓ 3.01% |
Total Liabilities | 54.9M | ↓ 10.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 328.2M | ↓ 0.22% |
Total Liabilities | 57.7M | ↑ 5.11% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 270.6M | ↓ 17.53% |
Total Liabilities | 58.4M | ↑ 1.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 263.7M | ↓ 2.55% |
Total Liabilities | 55.2M | ↓ 5.41% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 262.7M | ↓ 0.41% |
Total Liabilities | 52.3M | ↓ 5.24% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 231.4M | ↓ 11.9% |
Total Liabilities | 51.5M | ↓ 1.48% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 34.9M | ↓ 14.44% |
Investing Cash Flow | -50.3M | ↑ 302.7% |
Financing Cash Flow | -28.9M | ↓ 9305.1% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 37.0M | ↑ 5.98% |
Investing Cash Flow | 39.7M | ↓ 178.98% |
Financing Cash Flow | -8.1M | ↓ 71.83% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.1M | ↓ 64.69% |
Investing Cash Flow | -71.3M | ↓ 279.55% |
Financing Cash Flow | -3.8M | ↓ 53.65% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.4M | ↓ 35.73% |
Investing Cash Flow | -3.1M | ↓ 95.62% |
Financing Cash Flow | -6.8M | ↑ 79.62% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.4M | ↓ 47.49% |
Investing Cash Flow | -7.5M | ↑ 140.09% |
Financing Cash Flow | -4.9M | ↓ 28.43% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.6M | ↓ 852.18% |
Investing Cash Flow | -1.4M | ↓ 45.08% |
Financing Cash Flow | -1.6M | ↓ 341.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.3M | ↑ 129.22% |
Investing Cash Flow | -1.5M | ↑ 4.9% |
Financing Cash Flow | -4.9M | ↑ 206.45% |
Sell
Neutral
Buy
Anika Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Anika Therapeutics Inc | -29.9% | -38.73% | -19.48% | -62.09% | -72.74% |
Neurocrine Biosciences Inc. | 7.46% | -14.95% | 5.72% | 29.31% | 17.74% |
Haleon Plc Spon Ads | -2.69% | 18.45% | 20.35% | 31.71% | 31.71% |
Zoetis Inc. | -6.46% | 5.56% | 7.36% | -19.17% | 45.68% |
Viatris Inc. | 1.06% | -3.13% | 24.32% | -16.61% | -29.93% |
Catalent, Inc. | -3.17% | 4.12% | 71.21% | -51.98% | 16.38% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Anika Therapeutics Inc | NA | NA | 1.25 | -1.45 | -0.43 | -0.04 | NA | 12.18 |
Neurocrine Biosciences Inc. | 32.58 | 32.58 | 0.28 | 4.16 | 0.16 | 0.12 | NA | 26.87 |
Haleon Plc Spon Ads | 28.62 | 28.62 | 1.44 | 0.38 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 35.68 | 35.68 | 2.58 | 5.82 | 0.49 | 0.14 | 0.01 | 10.9 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 2.94 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Anika Therapeutics Inc | Buy | $252.6M | -72.74% | NA | -59.4% |
Neurocrine Biosciences Inc. | Buy | $12.4B | 17.74% | 32.58 | 17.21% |
Haleon Plc Spon Ads | Buy | $44.0B | 31.71% | 28.62 | 10.75% |
Zoetis Inc. | Buy | $82.4B | 45.68% | 35.68 | 26.29% |
Viatris Inc. | Hold | $13.9B | -29.93% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.7B | 16.38% | 211.02 | -23.81% |
Insights on Anika Therapeutics Inc
Revenue is down for the last 2 quarters, 41.92M → 38.75M (in $), with an average decrease of 7.6% per quarter
Netprofit is down for the last 2 quarters, -88.0K → -29.91M (in $), with an average decrease of 33897.7% per quarter
In the last 1 year, Catalent, Inc. has given 66.4% return, outperforming this stock by 85.6%
In the last 3 years, Anika Therapeutics Inc has experienced a drawdown of -62.1%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 10.1%
Trigran Investments Inc
BlackRock Inc
Caligan Partners LP
Morgan Stanley - Brokerage Accounts
Vanguard Group Inc
Dimensional Fund Advisors, Inc.
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
Organization | Anika Therapeutics Inc |
Employees | 357 |
CEO | Dr. Cheryl Renee Blanchard Ph.D. |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$16.30
-4.51%
Pimco Rafi Dynamic Multi-factor Emerging Markets Equity Etf
$16.30
-4.51%
Fidelity Msci Materials Etf
$16.30
-4.51%
Usana Health Sciences Inc.
$16.30
-4.51%
Spire Global Inc
$16.30
-4.51%
Flag Ship Acquisition Corp
$16.30
-4.51%
John Han Premium Dividend Fd
$16.30
-4.51%
Segall Bryant & Hamill Select Equity Etf
$16.30
-4.51%
Bristow Group Inc
$16.30
-4.51%